Understanding the variability in clinical and biological response to B-cell depletion therapy in rheumatoid arthritis and systemic lupus erythematosus
Factors including pharmacokinetics, B-cell internalisation of anti-CD20 monoclonal antibodies (mAbs) and disease-associated defects in complement system, NK cells and macrophages may influence the efficiency of rituximab, a Type I anti-CD20 mAb disposed to internalisation by B cells, and contribute...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2018
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.756187 |